Leslie Mataya, Andrew Aronsohn, J. Richard Thistlethwaite, Lainie Friedman Ross – 1 April 2014 – The liver donor risk index (LDRI), originally developed in 2006 by Feng et al. and since modified, is a method of evaluating liver grafts from deceased donors through the determination of the relative risk of graft failure after transplantation. Online and paper surveys about attitudes and practices regarding decision making in liver transplantation and the role of the LDRI were sent to liver transplant physicians.

Joachim Mertens – 1 April 2014 – Watch a video presentation of this article

Debashis Haldar, Gideon M. Hirschfield – 1 April 2014 – Watch a video presentation of this article

Debashis Haldar, Gideon M. Hirschfield – 1 April 2014 – Watch a video presentation of this article

Marcus Robertson, Avik Majumdar, Kent Garrett, Greg Rumler, Paul Gow, Adam Testro – 31 March 2014

Marcus Robertson, Avik Majumdar, Kent Garrett, Greg Rumler, Paul Gow, Adam Testro – 31 March 2014

Sangbin Han, Gaabsoo Kim, Suk‐Koo Lee, Choon Hyuck David Kwon, Misook Gwak, Sanghoon Lee, Sangyun Ha, Cheol‐Keun Park, Justin Sangwook Ko, Jaewon Joh – 31 March 2014 – A safe use of intermittent hepatic inflow occlusion (IHIO) has been reported for living donor hepatectomy. However, it remains unclear whether the maneuver is safe in steatotic donors. In addition, the respective importance of macrosteatosis (MaS) and microsteatosis (MiS) is an important issue. Thus, we compared MiS and MaS with respect to the tolerance of hepatic ischemia/reperfusion (IR) injury induced by IHIO.

Alan J. Wigg, Mohamed A. Chinnaratha, Rachel Wundke, Michael L. Volk – 28 March 2014

Liesl M. Hagan, Mark S. Sulkowski, Raymond F. Schinazi – 28 March 2014 – Treatment guidance for chronic hepatitis C (CHC) released by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) offers two options for interferon (IFN)‐ineligible/intolerant individuals with genotype 1 infection: sofosbuvir/ribavirin (SOF/RBV) for 24 weeks or sofosbuvir/simeprevir (SOF/SMV) for 12 weeks.

Liesl M. Hagan, Mark S. Sulkowski, Raymond F. Schinazi – 28 March 2014 – Treatment guidance for chronic hepatitis C (CHC) released by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) offers two options for interferon (IFN)‐ineligible/intolerant individuals with genotype 1 infection: sofosbuvir/ribavirin (SOF/RBV) for 24 weeks or sofosbuvir/simeprevir (SOF/SMV) for 12 weeks.